ProCE Banner Activity

Combining Chemotherapy With Immunotherapy to Treat ALL: A Novel Approach

Clinical Thought
How do you manage patients with ALL in the era of immunotherapy? In this commentary, Eunice S. Wang, MD, discusses a novel approach of combining chemotherapy with immunotherapy to treat patients with ALL.

Released: February 25, 2020

Expiration: February 23, 2021

Share

Faculty

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Jazz Pharmaceuticals, Inc.

Pfizer, Inc.

Faculty Disclosure

Primary Author

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD, has disclosed that she has received consulting fees from AbbVie, Agios, Amgen, Astellas, Celyad, Daiichi Sankyo, Jazz, Kite, Pfizer, and Stemline and honoraria from Pfizer and Stemline.